ReviewEndocrine-related cancer2020
Innovative imaging of insulinoma: the end of sampling? A review.
Review in Endocrine-related cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 79 citations in OpenAlex.
- Recurrent Syncope, Behavioral Changes and Weight Gain in an Elderly Filipino Woman: Successful Diagnosis and Management of Insulinoma With 13-Year Disease-Free Follow-up.Journal of the ASEAN Federation of Endocrine Societies · 2026Article
- Clinical Presentation and Outcomes of Insulinomas in Pediatric Patients.Hormone research in paediatrics · 2026Article
- Adult-Onset Nesidioblastosis: A Challenging Diagnosis Revealed by Endoscopic Ultrasonography.The American journal of case reports · 2026Article
- Congenital Hyperinsulinemic Hypoglycemia With a New HADH Mutation and Pancreatic Overexpression of GLP-1 Receptors.The Journal of clinical endocrinology and metabolism · 2026Article
- Targeted near-infrared imaging utilizing a cathepsin-activated fluorophore for the intraoperative detection of canine insulinoma.PloS one · 2026Article
- Illuminating the Uncinate: Advanced Indocyanine Green Fluorescence and Ultrasound-Guided Robotic Enucleation of a Pancreatic Insulinoma in a Challenging Position.Annals of surgical oncology · 2025Article
- 68 Ga-NODAGA-EXENDIN-4 PET/CT in the Detection or the Exclusion of Occult Sporadic Insulinomas.Clinical nuclear medicine · 2025Article
- Minimally Invasive Resection of Occult Insulinomas-Experience from an ENETS Centre of Excellence and Review of the Literature.Cancers · 2025Article
- Glucagon-like peptide-1 receptor PET/CT withEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Does X mark the spot? A case series of discrepant preoperative insulinoma localization.Endocrinology, diabetes & metabolism case reports · 2025Article
- Medically Refractory Nesidioblastosis as a Late Adverse Effect of Roux-en-Y Gastric Bypass.Cureus · 2025Article
- Comparison of Exendin-4 and Its Single Amino Acid Substitutions as Parent Peptides for GLP-1 Receptor Imaging Probes.Molecules (Basel, Switzerland) · 2025Article
- Diagnostic Challenges in Difficult-to-Localize Insulinomas: A Case Report and Review of Literature.Diagnostics (Basel, Switzerland) · 2024Article
- Article
- Approach to the Patient: Insulinoma.The Journal of clinical endocrinology and metabolism · 2024Article
- Long-term Survival in a Child with Malignant Insulinoma After Liver TransplantationJournal of clinical research in pediatric endocrinology · 2024Article
- Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas.International journal of molecular sciences · 2023Article
- DynamicQuantitative imaging in medicine and surgery · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Receptors for the incretin glucagon-like peptide-1 (GLP-1R) have been found overexpressed in selected types of human tumors and may, therefore, play an increasingly important role in endocrine gastrointestinal tumor management. In particular, virtually all benign insulinomas express GLP-1R in high density. Targeting GLP-1R with indium-111, technetium-99m or gallium-68-labeled exendin-4 offers a new approach that permits the successful localization of small benign insulinomas. It is likely that this new non-invasive technique has the potential to replace the invasive localization of insulinomas by selective arterial stimulation and venous sampling. In contrast to benign insulinomas, malignant insulin-secreting neuroendocrine tumors express GLP-1R in only one-third of the cases, while they more often express the somatostatin subtype 2 receptors. Importantly, one of the two receptors appears to be always overexpressed. In special cases of endogenous hyperinsulinemic hypoglycemia (EHH), that is, in the context of MEN-1 or adult nesidioblastosis GLP-1R imaging is useful whereas in postprandial hypoglycemia in the context of bariatric surgery, GLP-1R imaging is probably not helpful. This review focuses on the potential use of GLP-1R imaging in the differential diagnosis of EHH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.